This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
$1 buys you full access to ALL of TheStreet's Subscription Services! Learn More

Myrexis To Provide Update On Heat Shock Protein 90 And Cancer Metabolism Inhibitor Programs At 102nd Annual Meeting Of American Association For Cancer Research

Stocks in this article: MYRX

SALT LAKE CITY, March 17, 2011 (GLOBE NEWSWIRE) -- Myrexis, Inc. (Nasdaq:MYRX), a biotechnology company focused on discovering, developing, and commercializing novel treatments for cancer, today announced it will present nine posters at the 102 nd annual meeting of the American Association for Cancer Research (AACR), April 2 – 6, 2011, in Orlando, Florida.

The posters will highlight key preclinical findings from two of Myrexis' oncology programs: MPC-3100, its fully synthetic, orally-bioavailable, non-geldanamycin heat shock protein 90 (Hsp90) inhibitor, which is completing Phase 1 clinical studies in solid and hematological refractory cancer patients; and its unique cancer metabolism inhibitor, MPC-9528, which is currently in preclinical studies and has demonstrated dramatic tumor regression in animal models across multiple tumor types using a variety of dosing schedules.

Abstracts describing the upcoming presentations are available online at www.aacr.org.

MPC-3100:  
   
Poster Number: 2617
Title: MPC-3100, a Synthetic Hsp90 Inhibitor, Induces Biomarker Changes in vitro and in vivo
Date & Time: Monday, April 4, 2011; 1pm – 5pm
Location: Exhibit Hall A4-C, Poster Section 29
   
Poster Number: 2628
Title: Anti-Tumor Activity of MPC-3100, a Synthetic Hsp90 Inhibitor, in Combination with Erlotinib and Sorafenib
Date & Time: Monday, April 4, 2011; 1pm – 5pm
Location: Exhibit Hall A4-C, Poster Section 29
   
Poster Number: 3233
Title: Comparative in vitro and in vivo Metabolism of MPC-3100, an Oral Hsp90 Inhibitor in Rat, Dog, Monkey and Human
Date & Time: Tuesday, April 5, 2011; 8am – 12pm
Location: Exhibit Hall A4-C, Poster Section 15
   
Poster Number: 3237
Title: Evaluation of the Pharmacokinetics and Efficacy of a Novel Pro-Drug of the Hsp90 Inhibitor MPC-3100, Designed with Improved Solubility
Date & Time: Tuesday, April 5, 2011; 8am – 12pm
Location: Exhibit Hall A4-C, Poster Section 16
   
   
MPC-9528  
   
Poster Number: 577
Title: Co-Administration of Nicotinic Acid with the Nampt Inhibitor MPC-9528 Enhances Anti-Tumor Activity in Naprt Deficient Cancer Cells in Culture and in Xenografts
Date & Time: Sunday, April 3, 2011; 1pm – 5pm
Location: Exhibit Hall A4-C, Poster Section 25
   
   
Poster Number: 2551
Title: The Nampt Inhibitor MPC-9528 Synergizes with DNA Damaging Agents
Date & Time: Monday, April 4, 2011; 1pm – 5pm
Location: Exhibit Hall A4-C, Poster Section 27
   
Poster Number: 3526
Title: Basal NAD Levels and Nampt Expression Correlates with the Sensitivity of Tumor Cell Lines in vitro and in vivo to the Nampt Inhibitor MPC-9528
Date & Time: Tuesday, April 5, 2011; 8am – 12pm
Location: Exhibit Hall A4-C, Poster Section 27
   
Poster Number: 4386
Title: Administration of Nicotinic Acid Reduces or Prevents Adverse Effects of MPC-9528, a Potent and Selective Nampt Inhibitor
Date & Time: Tuesday, April 5, 2011; 1pm – 5pm
Location: Exhibit Hall A4-C, Poster Section 23
   
Poster Number: LB-393*
Title: The Cancer Metabolism Inhibitor MPC-9528 Induces Tumor Regression in Xenograft Models with Multiple Dosing Schedules
Date & Time: Tuesday, April 5, 2011; 1pm – 5pm
Location: Exhibit Hall A4-C, Poster Section 39
   
* Late-breaker poster  

About MPC-3100

MPC-3100 is a novel, fully-synthetic, orally-bioavailable, small-molecule inhibitor of heat shock protein 90 that is currently in Phase 1 clinical studies. MPC-3100 is structurally distinct from geldanamycin-derived Hsp90 inhibitors and this unique structure appears to reduce the off-target toxicities that are common to this group of drugs. In non-clinical studies, MPC-3100 demonstrated activity against multiple solid and hematological tumor cell lines, suggesting it may have the potential to treat a wide range of cancers. In the ongoing Phase 1 clinical study, MPC-3100 is administered orally on a daily, continuous schedule which non-clinical studies suggest may optimize drug exposure and improve outcomes.

1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,810.06 +91.06 0.51%
S&P 500 2,063.50 +10.75 0.52%
NASDAQ 4,712.97 +11.1030 0.24%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs